Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells |
| Synonyms | |
| Therapy Description |
IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells are autologous naïve and memory T cells (TN/MEM) engineered to express a chimeric antigen receptor (CAR) targeting interleukin-13 receptor alpha 2 (IL13Ra2), and containing the CD137 co-stimulatory signaling domain fused to CD3-zeta, and a truncated form of CD19, which may induce killing of to IL13Ra2-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells | IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells | IL13RA2 Immune Cell Therapy 7 | IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells are autologous naïve and memory T cells (TN/MEM) engineered to express a chimeric antigen receptor (CAR) targeting interleukin-13 receptor alpha 2 (IL13Ra2), and containing the CD137 co-stimulatory signaling domain fused to CD3-zeta, and a truncated form of CD19, which may induce killing of to IL13Ra2-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|